CTX — Crescita Therapeutics Share Price
0.000.00%
Last trade - 00:00- CA$10.83m
- CA$2.39m
- CA$19.58m
- 67
- 76
- 46
- 68
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.68 | ||
| Price to Tang. Book | 0.77 | ||
| Price to Free Cashflow | 7.03 | ||
| Price to Sales | 0.55 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -19.77% | ||
| Return on Equity | -15.87% | ||
| Operating Margin | -16.42% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 15.64 | 16.77 | 23.52 | 17.52 | 19.58 | n/a | n/a | -2.6% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -92.41 | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Crescita Therapeutics Inc. is a commercial dermatology company with in-house research and development (R&D) and manufacturing capabilities. It offers a portfolio of science-based non-prescription skincare products and early to commercial stage prescription products. It operates in three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The Commercial Skincare segment manufactures and sells branded non-prescription skincare products for the Canadian and international markets. It also commercializes Pliaglis, NCTF Boost 135 HA, ART FILLER, and Obagi Medical in Canada. The Licensing and Royalties segment engaged in licensing the intellectual property related to Pliaglis or its transdermal delivery technologies. Manufacturing and Services segment engaged in the sale of topical products manufactured to client specifications under the Company’s contract development and manufacturing organization infrastructure, and product development services.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 1st, 2016
- Public Since
- March 7th, 2016
- No. of Employees
- 80
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Toronto Stock Exchange
- Shares in Issue
- 19,005,492
- Address
- 2805, Place Louis R Renaud, LAVAL, H7V 0A3
- Web
- https://www.crescitatherapeutics.com/
- Phone
- +1 4506804722
- Auditors
- Ernst & Young LLP
Upcoming Events for CTX
Crescita Therapeutics Inc Extraordinary Shareholders Meeting
Crescita Therapeutics Inc Annual Shareholders Meeting
Crescita Therapeutics Inc Annual Shareholders Meeting
Q2 2025 Crescita Therapeutics Inc Earnings Release
Similar to CTX
Aptose Biosciences
Toronto Stock Exchange
Aurora Cannabis
Toronto Stock Exchange
Auxly Cannabis
Toronto Stock Exchange
Bausch Health Companies
Toronto Stock Exchange
Canopy Growth
Toronto Stock Exchange
FAQ
What is the Crescita Therapeutics share price?
As of Today at 20:05 UTC, shares in Crescita Therapeutics are trading at CA$0.57. This share price information is delayed by 15 minutes.
How has the Crescita Therapeutics share price performed this year?
Shares in Crescita Therapeutics last closed at CA$0.57 and the price had moved by +29.55% over the past 365 days. In terms of relative price strength the Crescita Therapeutics share price has outperformed the Toronto Stock Exchange 300 Composite Index by +15.17% over the past year.
What are the analyst and broker recommendations for Crescita Therapeutics?
There is no consensus recommendation for this security.
Find out moreWhat is the Crescita Therapeutics dividend yield?
Crescita Therapeutics does not currently pay a dividend.
Does Crescita Therapeutics pay a dividend?
Crescita Therapeutics does not currently pay a dividend.
When does Crescita Therapeutics next pay dividends?
Crescita Therapeutics does not currently pay a dividend.
How do I buy Crescita Therapeutics shares?
To buy shares in Crescita Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Crescita Therapeutics?
As of the previous close price of CA$0.57, shares in Crescita Therapeutics had a market capitalisation of CA$10.83m.
Where are Crescita Therapeutics shares listed?
Here are the trading details for Crescita Therapeutics:
- Country of listing: Canada
- Exchange: TOR
- Ticker Symbol: CTX
What kind of share is Crescita Therapeutics?
Based on an overall assessment of its quality, value and momentum Crescita Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Crescita Therapeutics share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Crescita Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Crescita Therapeutics. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -5.56%.
As of the last closing price of CA$0.57, shares in Crescita Therapeutics were trading +4.13% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Crescita Therapeutics PE Ratio?
The Crescita Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.57.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Crescita Therapeutics?
We do not have data on Crescita Therapeutics' directors